Enveric Biosciences, Inc.(ENVB)Earnings, Financials & Key Ratios
ENVB•NASDAQ
$3.18
$133267 mkt cap·Price updated May 6, 2026
AboutEnveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Show more
- Revenue$0
- EBITDA-$9M+42.1%
- Net Income-$10M-55272.4%
- EPS (Diluted)-228.48-135.4%
- ROE-539.57%-273098.0%
ENVB Key Insights
Enveric Biosciences, Inc. (ENVB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 76.7% through buybacks
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ENVB Price & Volume
Enveric Biosciences, Inc. (ENVB) stock price & volume — 10-year historical chart
Loading chart...
ENVB Growth Metrics
Enveric Biosciences, Inc. (ENVB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM1.26%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-16498.45%
Return on Capital
10 Years-133.73%
5 Years-219%
3 Years-276.65%
Last Year-542.79%
ENVB Peer Comparison
Enveric Biosciences, Inc. (ENVB) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CMPS | 937.8M | 9.76 | -3.17 | -335.93% | ||||
 MNMD | 2.04B | 20.69 | -10.04 | -55.3% | ||||
 ATAI | 1B | 4.17 | -4.48 | -1.91% | -51.09% | -96.43% | 0.21 | |
 CYBN | 303.86M | 6.09 | -13.66 | -81% | ||||
 LSCC | 17.15B | 125.19 | 5613.90 | 2.72% | 3.46% | 2.79% | 0.11 | |
 SILO | 1.89M | 0.42 | -0.35 | -70.41% | -101.36% | |||
 DRUG | 865.19M | 88.90 | -94.37 | -13.5% | 0.00 | |||
 JAZZ | 14.34B | 228.57 | -39.14 | 4.88% | 0.66% | 0.71% | 1.26 |
Compare ENVB vs Peers
Enveric Biosciences, Inc. (ENVB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ENVB Income Statement
Enveric Biosciences, Inc. (ENVB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 36.15M | 48.59M | 43M | 39.91M | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | 126.24% | 34.44% | -11.51% | -7.17% | -100% | - | - | - | - | - |
| Cost of Goods Sold | 29.61M | 38.36M | 34.01M | 31.76M | 120.87K | 681.61K | 435.2K | 408.03K | 337.49K | 243.86K |
| COGS % of Revenue | 81.92% | 78.93% | 79.11% | 79.58% | - | - | - | - | - | - |
| Gross Profit | 6.54M▲ 0% | 10.24M▲ 56.6% | 8.98M▼ 12.3% | 8.15M▼ 9.3% | -120.87K▼ 101.5% | -681.61K▼ 463.9% | -435.2K▲ 36.2% | -408.03K▲ 6.2% | -337.49K▲ 17.3% | -243.86K▲ 0% |
| Gross Margin % | 18.08% | 21.07% | 20.89% | 20.42% | - | - | - | - | - | - |
| Gross Profit Growth % | 13.66% | 56.62% | -12.25% | -9.27% | -101.48% | -463.91% | 36.15% | 6.24% | 17.29% | - |
| Operating Expenses | 10.33M | 21.73M | 13.7M | 14.48M | 5.5M | 25.26M | 19.53M | 16.04M | 9.29M | 9.51M |
| OpEx % of Revenue | 28.58% | 44.71% | 31.86% | 36.27% | - | - | - | - | - | - |
| Selling, General & Admin | 8.97M | 18.51M | 10.79M | 12.21M | 5.32M | 20.47M | 11.5M | 8.79M | 6.45M | 6M |
| SG&A % of Revenue | 24.82% | 38.09% | 25.11% | 30.59% | - | - | - | - | - | - |
| Research & Development | 0 | 0 | 0 | 0 | 174.08K | 4.79M | 8.03M | 7.25M | 2.84M | 3.51M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -394.21K | 1.08M | 88.16K | 2.27M | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -5.38M▲ 0% | -11.97M▼ 122.5% | -7.15M▲ 40.3% | -6.32M▲ 11.5% | -5.62M▲ 11.2% | -25.94M▼ 361.9% | -19.96M▲ 23.1% | -16.45M▲ 17.6% | -9.63M▲ 41.4% | -9.75M▲ 0% |
| Operating Margin % | -14.88% | -24.63% | -16.62% | -15.85% | - | - | - | - | - | - |
| Operating Income Growth % | -187.59% | -122.51% | 40.3% | 11.5% | 11.19% | -361.87% | 23.06% | 17.6% | 41.44% | - |
| EBITDA | -4.02M | -8.75M | -4.24M | -4.06M | -5.5M | -25.26M | -19.53M | -16.04M | -9.29M | -9.51M |
| EBITDA Margin % | -11.12% | -18.01% | -9.87% | -10.17% | - | - | - | - | - | - |
| EBITDA Growth % | -134.64% | -117.82% | 51.53% | 4.32% | -35.39% | -359.62% | 22.71% | 17.85% | 42.05% | -11.85% |
| D&A (Non-Cash Add-back) | 1.36M | 3.22M | 2.9M | 2.27M | 120.87K | 681.61K | 435.2K | 408.03K | 337.49K | 243.86K |
| EBIT | -5.77M | -10.89M | -9.82M | -4.52M | -6.42M | -56.42M | -19.95M | -17.26M | -9.57M | -7.85M |
| Net Interest Income | -751.07K | -575.04K | -729.9K | -691.14K | -444.81K | -10.31K | -5.24K | -3.71K | 219 | -83 |
| Interest Income | 0 | 0 | 0 | 0 | 445 | 10 | 5 | 0 | 219 | 49 |
| Interest Expense | 751.07K | 575.04K | 729.9K | 691.14K | 445.25K | 10.32K | 5.25K | 3.71K | 0 | 132 |
| Other Income/Expense | -2.73M | -11.47M | -10.55M | 1.11M | -1.25M | -30.49M | 4.05K | -814.38K | 66.21K | 29.09K |
| Pretax Income | -6.53M▲ 0% | -11.47M▼ 75.7% | -10.55M▲ 8.0% | -5.22M▲ 50.6% | -6.86M▼ 31.6% | -56.43M▼ 722.1% | -19.96M▲ 64.6% | -17.26M▲ 13.5% | -9.57M▲ 44.6% | -9.73M▲ 0% |
| Pretax Margin % | -18.05% | -23.6% | -24.53% | -13.07% | - | - | - | - | - | - |
| Income Tax | -3.75M | -2.39M | 6.35M | 388.66K | 0 | -7.45M | -1.49M | 28.91K | 8.93K | 7.2K |
| Effective Tax Rate % | 57.44% | 20.86% | -60.18% | -7.45% | 0% | 13.21% | 7.45% | -0.17% | -0.09% | -0.07% |
| Net Income | -2.78M▲ 0% | -9.07M▼ 226.4% | -16.9M▼ 86.2% | -5.6M▲ 66.8% | -6.86M▼ 22.5% | -48.98M▼ 613.5% | -18.5M▲ 62.2% | -17.29K▲ 99.9% | -9.57M▼ 55272.4% | -9.73M▲ 0% |
| Net Margin % | -7.69% | -18.67% | -39.3% | -14.04% | - | - | - | - | - | - |
| Net Income Growth % | -47.07% | -226.35% | -86.2% | 66.84% | -22.5% | -613.46% | 62.22% | 99.91% | -55273.21% | 1.26% |
| Net Income (Continuing) | -2.78M | -9.07M | -16.9M | -5.6M | -6.86M | -48.98M | -18.47M | -17.29M | -9.57M | -9.73M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19.04K | 0 | 0 |
| Minority Interest | 3.38K | 0 | 0 | 0 | 0 | 0 | 885.03K | 0 | 0 | 0 |
| EPS (Diluted) | -12770.04▲ 0% | -36347.76▼ 184.6% | -42616.68▼ 17.2% | -2543.88▲ 94.0% | -666.00▲ 73.8% | -1244.28▼ 86.8% | -156.00▲ 87.5% | -97.08▲ 37.8% | -228.48▼ 135.4% | -31.07▲ 0% |
| EPS Growth % | -24.95% | -184.63% | -17.25% | 94.03% | 73.82% | -86.83% | 87.46% | 37.77% | -135.35% | -16498.45% |
| EPS (Basic) | -12770.04 | -36347.76 | -42616.68 | -2543.88 | -666.00 | -1244.28 | -87.72 | -97.08 | -228.48 | - |
| Diluted Shares Outstanding | 218 | 250 | 396 | 2.2K | 9.59K | 39.36K | 173.19K | 179.92K | 41.91K | 313.24K |
| Basic Shares Outstanding | 218 | 250 | 396 | 2.2K | 9.59K | 39.36K | 210.63K | 210.63K | 41.91K | 313.24K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ENVB Balance Sheet
Enveric Biosciences, Inc. (ENVB) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 10.06M | 14.64M | 10.06M | 7.6M | 2.28M | 17.74M | 18.43M | 3.58M | 2.73M | 4.17M |
| Cash & Short-Term Investments | 1.46M | 4.88M | 1.37M | 431.4K | 1.58M | 17.36M | 17.72M | 2.29M | 2.24M | 3.76M |
| Cash Only | 1.38M | 4.88M | 1.37M | 431.4K | 1.58M | 17.36M | 17.72M | 2.29M | 2.24M | 3.76M |
| Short-Term Investments | 82.91K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 8.06M | 8.84M | 7.87M | 6.38M | 0 | 0 | 0 | 224.61K | 0 | 0 |
| Days Sales Outstanding | 81.39 | 66.39 | 66.82 | 58.38 | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | 24.48 |
| Other Current Assets | 542.24K | 924.27K | 818.6K | 718.53K | 700.71K | 0 | 159.78K | 567.6K | 0 | 407.95K |
| Total Non-Current Assets | 29.44M | 37.55M | 19.58M | 17.41M | 1.82M | 8.98M | 1.12M | 718.31K | 347.96K | 196.52K |
| Property, Plant & Equipment | 100.24K | 95.05K | 58.89K | 83.13K | 0 | 470.73K | 741.3K | 507.38K | 305.78K | 196.52K |
| Fixed Asset Turnover | 360.59x | 511.25x | 730.12x | 480.16x | - | - | - | - | - | 0.00x |
| Goodwill | 17.09M | 21.9M | 13.73M | 13.73M | 0 | 1.59M | 0 | 0 | 0 | 0 |
| Intangible Assets | 8.76M | 9.47M | 5.78M | 3.58M | 1.82M | 6.92M | 379.69K | 210.93K | 42.18K | 0 |
| Long-Term Investments | 0 | -6.18M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 6.18M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 39.51M▲ 0% | 52.2M▲ 32.1% | 29.64M▼ 43.2% | 25.01M▼ 15.6% | 4.1M▼ 83.6% | 26.72M▲ 552.2% | 19.55M▼ 26.8% | 4.3M▼ 78.0% | 3.08M▼ 28.3% | 4.36M▲ 0% |
| Asset Turnover | 0.91x | 0.93x | 1.45x | 1.60x | - | - | - | - | - | 0.00x |
| Asset Growth % | 185.57% | 32.12% | -43.22% | -15.63% | -83.62% | 552.18% | -26.82% | -78.01% | -28.31% | -120.96% |
| Total Current Liabilities | 12.71M | 30.37M | 14.69M | 14.38M | 681.25K | 2.08M | 4M | 2.34M | 1.49M | 905.88K |
| Accounts Payable | 5.13M | 5.32M | 4.38M | 4.7M | 681.25K | 683.39K | 463.27K | 1.22M | 521.75K | 683.71K |
| Days Payables Outstanding | 63.25 | 50.67 | 46.98 | 53.97 | 2.06K | 365.95 | 388.55 | 1.09K | 564.28 | 1.09K |
| Short-Term Debt | 3.49M | 4.8M | 5.21M | 4.88M | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | -2.58M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 564.24K | 20.24M | 3.8M | 737.79K | 0 | 0 | 1.76M | 350.72K | 3.09K | 222.18K |
| Current Ratio | 0.79x | 0.48x | 0.68x | 0.53x | 3.35x | 8.51x | 4.61x | 1.53x | 1.84x | 1.84x |
| Quick Ratio | 0.79x | 0.48x | 0.68x | 0.53x | 3.35x | 8.51x | 4.61x | 1.53x | 1.84x | 1.84x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -1.07K |
| Total Non-Current Liabilities | 15.14M | 2.38M | 4.19M | 0 | 0 | 2.33M | 0 | 0 | 0 | 0 |
| Long-Term Debt | 1.54M | 2.38M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 68.86K | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 13.6M | 0 | 4.19M | 0 | 0 | 2.26M | 0 | 0 | 0 | 0 |
| Total Liabilities | 27.84M | 32.75M | 18.88M | 14.38M | 681.25K | 4.41M | 4M | 2.34M | 1.49M | 905.88K |
| Total Debt | 5.03M | 7.18M | 5.21M | 4.88M | 0 | 176.3K | 63.82K | 0 | 0 | 0 |
| Net Debt | 3.65M | 2.3M | 3.84M | 4.45M | -1.58M | -17.18M | -17.66M | -2.29M | -2.24M | -3.76M |
| Debt / Equity | 0.43x | 0.37x | 0.48x | 0.46x | - | 0.01x | 0.00x | - | - | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.40x |
| Interest Coverage | -7.16x | -20.82x | -9.79x | -9.15x | -12.62x | -2514.98x | -3802.90x | -4435.93x | - | -59481.80x |
| Total Equity | 11.66M▲ 0% | 19.44M▲ 66.7% | 10.76M▼ 44.7% | 10.62M▼ 1.3% | 3.42M▼ 67.8% | 22.31M▲ 553.1% | 15.56M▼ 30.3% | 1.96M▼ 87.4% | 1.59M▼ 18.6% | 3.46M▲ 0% |
| Equity Growth % | 4411.49% | 66.71% | -44.67% | -1.28% | -67.84% | 553.05% | -30.26% | -87.42% | -18.58% | -130.26% |
| Book Value per Share | 53503.22 | 77779.20 | 27169.44 | 4821.40 | 356.20 | 566.69 | 89.83 | 10.87 | 38.01 | 11.03 |
| Total Shareholders' Equity | 11.66M | 19.44M | 10.76M | 10.62M | 3.42M | 22.31M | 14.67M | 1.96M | 1.59M | 3.46M |
| Common Stock | 138.86K | 181.63K | 423.29K | 25.22K | 100.95K | 6.52K | 20.78K | 27.39K | 6.78K | 5.18K |
| Retained Earnings | -3.83M | -15M | -34.48M | -40.51M | -11.76M | -60.74M | -79.21M | -96.5M | -106.07M | -112.65M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -7.43K | 36.88K | 87K | 60.01K | -181.28K | -30.8K | -536.73K | -569.75K | -594.52K | -580.95K |
| Minority Interest | 3.38K | 0 | 0 | 0 | 0 | 0 | 885.03K | 0 | 0 | 0 |
ENVB Cash Flow Statement
Enveric Biosciences, Inc. (ENVB) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -2.7M | -2.74M | -2.57M | -647.86K | -3.89M | -11.46M | -17.15M | -14.09M | -7.73M | -7.73M |
| Operating CF Margin % | -7.48% | -5.64% | -5.97% | -1.62% | - | - | - | - | - | - |
| Operating CF Growth % | 26.35% | -1.36% | 6.4% | 74.75% | -500.25% | -194.63% | -49.65% | 17.8% | 45.18% | -56.18% |
| Net Income | -2.78M | -11.16M | -16.9M | -2.41M | -6.86M | -48.98M | -18.47M | -17.29M | -9.57M | -9.73M |
| Depreciation & Amortization | 1.36M | 3.22M | 2.9M | 0 | 120.87K | 681.61K | 435.2K | 408.03K | 337.49K | 243.86K |
| Stock-Based Compensation | 1.46M | 7.08M | 1.25M | 0 | 1.98M | 12.6M | 2.62M | 2.15M | 1.56M | 871.78K |
| Deferred Taxes | -3.49M | -2.39M | 6.35M | 0 | 0 | -7.45M | -1.5M | 0 | 0 | 0 |
| Other Non-Cash Items | 528.39K | 1.06M | 4.86M | 738.5K | 1.25M | 30.51M | -9.3K | 813.88K | 372.21K | 467.33K |
| Working Capital Changes | 218.45K | -539.78K | -1.03M | 1.02M | -369.5K | 1.19M | -217.66K | -174.75K | -423.24K | 481.26K |
| Change in Receivables | -3.19M | -778.54K | 967.03K | 1.49M | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 3.6M | 620.79K | -2.1M | 222.68K | 0 | 383.2K | 263.69K | -103.85K | -834.63K | 166.29K |
| Cash from Investing | -6.59M | -808.88K | -3.64M | 0 | -44.14K | 2.19M | -584.16K | 11.67K | 0 | 0 |
| Capital Expenditures | -3.69M | -4.84K | 0 | 0 | -44.14K | -864.72K | -584.16K | -5.18K | 0 | 0 |
| CapEx % of Revenue | 10.21% | 0.01% | - | - | - | - | - | - | - | - |
| Acquisitions | -2.9M | -804.04K | -3.65M | 0 | 0 | 3.06M | 958.04K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -2.9B | -804.04K | 6.42K | 0 | 0 | -675 | -958.04K | 16.85K | 0 | 0 |
| Cash from Financing | 8.8M | 7.05M | 2.69M | 560K | 5.53M | 24.9M | 18.18M | -1.34M | 7.67M | 8.35M |
| Debt Issued (Net) | 3.79M | 0 | -1.98M | 538K | 1.67M | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 0 | 488K | 1000K | 1000K | -1000K | 1000K | 1.45M |
| Dividends Paid | 0 | -2.09B | -2.09T | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.08M | 1.08M |
| Other Financing | 3.38K | 2.09B | -1.66M | 22K | 3.37M | 3.29M | 958.04K | -291.08K | 4.3M | 1.78M |
| Net Change in Cash | -498.15K▲ 0% | 3.5M▲ 803.0% | -3.51M▼ 200.2% | -1.33M▲ 62.2% | 1.53M▲ 215.6% | 15.78M▲ 928.0% | 367.88K▼ 97.7% | -15.44M▼ 4295.9% | -46.95K▲ 99.7% | 645.91K▲ 0% |
| Free Cash Flow | -6.39M▲ 0% | -2.75M▲ 57.1% | -2.57M▲ 6.6% | -647.86K▲ 74.7% | -3.93M▼ 507.1% | -12.32M▼ 213.3% | -17.73M▼ 43.9% | -14.1M▲ 20.5% | -7.73M▲ 45.2% | -7.67M▲ 0% |
| FCF Margin % | -17.69% | -5.65% | -5.97% | -1.62% | - | - | - | - | - | - |
| FCF Growth % | -19.32% | 57.05% | 6.56% | 74.75% | -507.06% | -213.31% | -43.89% | 20.48% | 45.2% | 6.09% |
| FCF per Share | -29325.62 | -10982.54 | -6478.52 | -294.08 | -410.15 | -313.05 | -102.38 | -78.37 | -184.36 | -184.36 |
| FCF Conversion (FCF/Net Income) | 0.97x | 0.30x | 0.15x | 0.12x | 0.57x | 0.23x | 0.93x | 815.10x | 0.81x | 0.79x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.51K | 5K | -24K |
ENVB Key Ratios
Enveric Biosciences, Inc. (ENVB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -46.65% | -58.34% | -111.89% | -52.42% | -97.81% | -380.82% | -97.74% | -0.2% | -539.57% | -281.6% |
| Return on Invested Capital (ROIC) | -40.49% | -48.45% | -29.5% | -31.98% | -49.83% | -558.88% | -990.44% | - | - | 1547.06% |
| Gross Margin | 18.08% | 21.07% | 20.89% | 20.42% | - | - | - | - | - | - |
| Net Margin | -7.69% | -18.67% | -39.3% | -14.04% | - | - | - | - | - | - |
| Debt / Equity | 0.43x | 0.37x | 0.48x | 0.46x | - | 0.01x | 0.00x | - | - | 0.00x |
| Interest Coverage | -7.16x | -20.82x | -9.79x | -9.15x | -12.62x | -2514.98x | -3802.90x | -4435.93x | - | -59481.80x |
| FCF Conversion | 0.97x | 0.30x | 0.15x | 0.12x | 0.57x | 0.23x | 0.93x | 815.10x | 0.81x | 0.79x |
| Revenue Growth | 126.24% | 34.44% | -11.51% | -7.17% | -100% | - | - | - | - | - |
ENVB Frequently Asked Questions
Enveric Biosciences, Inc. (ENVB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Enveric Biosciences, Inc. (ENVB) grew revenue by 0.0% over the past year. Growth has been modest.
Enveric Biosciences, Inc. (ENVB) reported a net loss of $9.7M for fiscal year 2024.
Dividend & Returns
Enveric Biosciences, Inc. (ENVB) has a return on equity (ROE) of -539.6%. Negative ROE indicates the company is unprofitable.
Enveric Biosciences, Inc. (ENVB) had negative free cash flow of $7.7M in fiscal year 2024, likely due to heavy capital investments.
Explore More ENVB
Enveric Biosciences, Inc. (ENVB) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates